What additional drug is included in Triumeq along with Abacavir and Lamivudine?

Triumeq is an antiretroviral medication used for the treatment of HIV. It is a fixed-dose combination that contains three active ingredients: Abacavir, Lamivudine, and Dolutegravir. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that works by preventing the integration of viral DNA into the host's genome, thus inhibiting replication of the virus.

The combination of Abacavir and Lamivudine, both nucleoside reverse transcriptase inhibitors (NRTIs), alongside Dolutegravir provides a comprehensive approach to HIV treatment, effectively targeting the virus at multiple stages of its lifecycle. This synergistic effect is crucial for managing HIV infection and optimizing patient outcomes.

The other drugs listed, Efavirenz, Rilpivirine, and Emtricitabine, are used in other HIV treatment regimens but are not components of Triumeq. Hence, the correct inclusion of Dolutegravir with Abacavir and Lamivudine forms the complete formulation of Triumeq.